<p><strong>优信有限公司</strong> (NASDAQ:UXIN) 的股票在经历了一段动荡期后，最近一个月表现非常出色，涨幅达到 29%。并不是所有股东都会感到欢欣鼓舞，因为过去十二个月股价仍然下跌了令人失望的 25%。</p>
<p>在经历如此大幅的价格跳升后，考虑到美国特种零售行业中几乎一半的公司市销率（&#34;P/S&#34;）低于 0.5 倍，你可能会认为优信的 1.8 倍市销率并不值得研究。然而，市销率可能因某种原因而偏高，需要进一步调查以确定其合理性。</p>
<p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行工作。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前布局。</p>
<p>查看我们对优信的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/568468226-ps-multiple-vs-industry-1-dark-2/1767178485974?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/568468226-ps-multiple-vs-industry-1-dark-2/1767178485974"/></p>
<p>NasdaqGS:UXIN 市销率与行业比较 2025 年 12 月 31 日</p>
<h3>优信的市销率对股东意味着什么？</h3>
<p>优信最近的表现确实不错，其收入增长超过了大多数其他公司。似乎许多人预计强劲的收入表现将持续，这提高了市销率。然而，如果情况并非如此，投资者可能会因支付过高的股价而受到损失。</p>
<p>想知道分析师如何看待优信的未来与行业的对比吗？在这种情况下，我们的 <strong>免费</strong> 报告是一个很好的起点。</p>
<h2>收入增长指标告诉我们关于高市销率的什么？</h2>
<p>为了证明其市销率的合理性，优信需要实现超过行业的显著增长。</p>
<p>如果我们回顾过去一年的收入增长，该公司实现了 73% 的惊人增长。与三年前相比，收入总共也增长了 25%，这主要得益于过去 12 个月的增长。因此，我们可以首先确认该公司在这段时间内确实做得很好。</p>
<p>展望未来，根据跟踪该公司的两位分析师的预测，预计收入将在未来三年内每年增长 88%。与此同时，行业其他公司的年均增长率仅为 7.7%，显然吸引力较低。</p>
<p>考虑到这一点，优信的市销率高于大多数其他公司是可以理解的。显然，股东们不愿意抛售可能瞄准更繁荣未来的股票。</p>
<h2>最终结论</h2>
<p>优信股票的大幅反弹使公司的市销率大幅提升。有人认为，在某些行业中，市销率是一个较差的价值衡量标准，但它可以是一个强有力的商业情绪指标。</p>
<p>正如我们所怀疑的，我们对优信分析师预测的审查显示，其优越的收入前景正在推动其高市销率。在这一阶段，投资者认为收入恶化的潜力相当小，从而证明了这一高市销率的合理性。除非分析师们真的失误，否则这些强劲的收入预测应该会保持股价的稳定。</p>
<p>话虽如此，请注意 <strong>优信在我们的投资分析中显示出 3 个警告信号</strong>，其中 2 个信号有些不太令人愉快。</p>
<p>如果这些 <strong>风险让你重新考虑对优信的看法</strong>，请浏览我们的高质量股票互动列表，以了解还有什么其他选择。</p>
<p>移动基础设施用于国防和灾难</p>
<p>下一波机器人技术不是类人型的。它是完全自主的塔楼，在 30 分钟内提供 5G、ISR 和雷达服务，随时随地。</p>
<p>在下一轮合同之前获取投资者简报</p>
<p>由 CiTech 赞助</p>

优信

<p>优信有限公司 (NASDAQ:UXIN) 的股价最近上涨了 29%，尽管过去一年仍下跌了 25%。该公司的市销率 (P/S) 为 1.8 倍，高于许多专业零售行业的公司，这引发了对其估值的质疑。优信在过去一年中显示出 73% 的显著收入增长，预计在未来三年将以 88% 的年增长率增长，超过行业平均水平的 7.7%。尽管前景乐观，但投资者应谨慎，因为投资分析中存在三个警示信号</p>

<p><strong>Uxin Limited</strong> (NASDAQ:UXIN) shares have had a really impressive month, gaining 29% after a shaky period beforehand. Not all shareholders will be feeling jubilant, since the share price is still down a very disappointing 25% in the last twelve months.</p>
<div class="lb-trans"><p><strong>优信有限公司</strong> (NASDAQ:UXIN) 的股票在经历了一段动荡期后，最近一个月表现非常出色，涨幅达到 29%。并不是所有股东都会感到欢欣鼓舞，因为过去十二个月股价仍然下跌了令人失望的 25%。</p>
</div><p>After such a large jump in price, when almost half of the companies in the United States' Specialty Retail industry have price-to-sales ratios (or &#34;P/S&#34;) below 0.5x, you may consider Uxin as a stock probably not worth researching with its 1.8x P/S ratio. However, the P/S might be high for a reason and it requires further investigation to determine if it's justified.</p>
<div class="lb-trans"><p>在经历如此大幅的价格跳升后，考虑到美国特种零售行业中几乎一半的公司市销率（&#34;P/S&#34;）低于 0.5 倍，你可能会认为优信的 1.8 倍市销率并不值得研究。然而，市销率可能因某种原因而偏高，需要进一步调查以确定其合理性。</p>
</div><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p>
<div class="lb-trans"><p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行工作。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前布局。</p>
</div><p>See our latest analysis for Uxin</p>
<div class="lb-trans"><p>查看我们对优信的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/568468226-ps-multiple-vs-industry-1-dark-2/1767178485974" alt="" original-src="https://images.simplywall.st/asset/chart/568468226-ps-multiple-vs-industry-1-dark-2/1767178485974"/></p>
<p>NasdaqGS:UXIN Price to Sales Ratio vs Industry December 31st 2025</p>
<div class="lb-trans"><p>NasdaqGS:UXIN 市销率与行业比较 2025 年 12 月 31 日</p>
</div><h3>What Does Uxin's P/S Mean For Shareholders?</h3>
<div class="lb-trans"><h3>优信的市销率对股东意味着什么？</h3>
</div><p>Uxin certainly has been doing a good job lately as it's been growing revenue more than most other companies. It seems that many are expecting the strong revenue performance to persist, which has raised the P/S. However, if this isn't the case, investors might get caught out paying too much for the stock.</p>
<div class="lb-trans"><p>优信最近的表现确实不错，其收入增长超过了大多数其他公司。似乎许多人预计强劲的收入表现将持续，这提高了市销率。然而，如果情况并非如此，投资者可能会因支付过高的股价而受到损失。</p>
</div><p>Keen to find out how analysts think Uxin's future stacks up against the industry? In that case, our <strong>free</strong> report is a great place to start.</p>
<div class="lb-trans"><p>想知道分析师如何看待优信的未来与行业的对比吗？在这种情况下，我们的 <strong>免费</strong> 报告是一个很好的起点。</p>
</div><h2>What Are Revenue Growth Metrics Telling Us About The High P/S?</h2>
<div class="lb-trans"><h2>收入增长指标告诉我们关于高市销率的什么？</h2>
</div><p>In order to justify its P/S ratio, Uxin would need to produce impressive growth in excess of the industry.</p>
<div class="lb-trans"><p>为了证明其市销率的合理性，优信需要实现超过行业的显著增长。</p>
</div><p>If we review the last year of revenue growth, the company posted a terrific increase of 73%. Revenue has also lifted 25% in aggregate from three years ago, mostly thanks to the last 12 months of growth. So we can start by confirming that the company has actually done a good job of growing revenue over that time.</p>
<div class="lb-trans"><p>如果我们回顾过去一年的收入增长，该公司实现了 73% 的惊人增长。与三年前相比，收入总共也增长了 25%，这主要得益于过去 12 个月的增长。因此，我们可以首先确认该公司在这段时间内确实做得很好。</p>
</div><p>Looking ahead now, revenue is anticipated to climb by 88% per year during the coming three years according to the two analysts following the company. Meanwhile, the rest of the industry is forecast to only expand by 7.7% per year, which is noticeably less attractive.</p>
<div class="lb-trans"><p>展望未来，根据跟踪该公司的两位分析师的预测，预计收入将在未来三年内每年增长 88%。与此同时，行业其他公司的年均增长率仅为 7.7%，显然吸引力较低。</p>
</div><p>In light of this, it's understandable that Uxin's P/S sits above the majority of other companies. Apparently shareholders aren't keen to offload something that is potentially eyeing a more prosperous future.</p>
<div class="lb-trans"><p>考虑到这一点，优信的市销率高于大多数其他公司是可以理解的。显然，股东们不愿意抛售可能瞄准更繁荣未来的股票。</p>
</div><h2>The Final Word</h2>
<div class="lb-trans"><h2>最终结论</h2>
</div><p>The large bounce in Uxin's shares has lifted the company's P/S handsomely. It's argued the price-to-sales ratio is an inferior measure of value within certain industries, but it can be a powerful business sentiment indicator.</p>
<div class="lb-trans"><p>优信股票的大幅反弹使公司的市销率大幅提升。有人认为，在某些行业中，市销率是一个较差的价值衡量标准，但它可以是一个强有力的商业情绪指标。</p>
</div><p>As we suspected, our examination of Uxin's analyst forecasts revealed that its superior revenue outlook is contributing to its high P/S. At this stage investors feel the potential for a deterioration in revenues is quite remote, justifying the elevated P/S ratio. Unless the analysts have really missed the mark, these strong revenue forecasts should keep the share price buoyant.</p>
<div class="lb-trans"><p>正如我们所怀疑的，我们对优信分析师预测的审查显示，其优越的收入前景正在推动其高市销率。在这一阶段，投资者认为收入恶化的潜力相当小，从而证明了这一高市销率的合理性。除非分析师们真的失误，否则这些强劲的收入预测应该会保持股价的稳定。</p>
</div><p>Having said that, be aware <strong>Uxin is showing 3 warning signs</strong> in our investment analysis, and 2 of those are a bit unpleasant.</p>
<div class="lb-trans"><p>话虽如此，请注意 <strong>优信在我们的投资分析中显示出 3 个警告信号</strong>，其中 2 个信号有些不太令人愉快。</p>
</div><p>If these <strong>risks are making you reconsider your opinion on Uxin</strong>, explore our interactive list of high quality stocks to get an idea of what else is out there.</p>
<div class="lb-trans"><p>如果这些 <strong>风险让你重新考虑对优信的看法</strong>，请浏览我们的高质量股票互动列表，以了解还有什么其他选择。</p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>移动基础设施用于国防和灾难</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波机器人技术不是类人型的。它是完全自主的塔楼，在 30 分钟内提供 5G、ISR 和雷达服务，随时随地。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一轮合同之前获取投资者简报</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>由 CiTech 赞助</p>
</div>

优信有限公司（纳斯达克股票代码：UXIN）股价上涨 29%，看起来正合适